

IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Esmail Behboodi et al.

Art Unit No.: 1632

Application No.: 10/731,542

Examiner: Unknown

Filed: December 9, 2003

For: **METHOD SYSTEM FOR UTILIZING SEMATIC CELL NUCLEAR TRANSFER
EMBRYOS AS CELL DONORS FOR ADDITIONAL NUCLEAR TRANSFER**

Attorney Docket Number: GTC-60

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
WITHIN THREE MONTHS OF FILING APPLICATION OR BEFORE MAILING OF A
FIRST OFFICE ACTION ON THE MERITS (37 CFR 1.97(b))**

1. Authority

Pursuant to 37 CFR §§ 1.56 and 1.97-1.99, the Applicant cites to the Examiner documents containing information which, in good-faith judgment of the Applicant, may be relevant to the subject matter claimed in the above-identified application. The Applicant also encloses copies of the English-language cited documents.

In submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, or the extent of any search performed, or that more relevant information does not exist.


In submitting this Information Disclosure Statement, the Applicant makes no representation that any document cited in this Information Disclosure Statement is, or is considered to be prior art as defined by 35 USC §§ 102 and 103.

2. Time of Transmittal of Accompanying Information Disclosure Statement

The Information Disclosure Statement transmitted herewith is being filed *after* three months of the filing date of this national application but *before* the mailing date of the first Office action on the merits.

CERTIFICATE OF MAILING (37 CFR 1.8a)

I hereby certify that on March 1, 2005 this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Dawn Corey Greenaway

It is Applicant's understanding that no fee is due; however, if the Applicant is incorrect, please charge any necessary fees for the above-captioned application to Deposit Account No. 502092.

The Applicant respectfully requests that:


- a. The Examiner consider the cited information in reaching a determination concerning the patentability of the pending claims; and
- b. The enclosed Form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

The person making this statement is the attorney who signs below on the basis of the information in the attorney's file.

Respectfully submitted,

Dated: 12/21/24

By:


Byron V. Olsen, Reg. No. 42,960
Attorney for Applicants
Taurus hSA LLC
175 Crossing Blvd., Suite 410
Framingham, MA 01702
Tel. #(508) 370-5150 Fax #(508) 370-3797

Under the Paperwork Reduction Act of 1995, no person shall be required to provide information unless it displays a valid control number.

Substitute for form 1449A/PTO

MAR 03 2005

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	10/731,542
Filing Date	December 3, 2003
First Named Inventor	Esmail Behboodi
Art Unit	1632
Examiner Name	
Attorney Docket Number	GTC-60

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901/04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/731,542
				Filing Date	December 3, 2003
				First Named Inventor	Esmail Behboodi
				Group Art Unit	1632
Examiner Name					
Sheet	2	of	4	Attorney Docket Number	GTC-60

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Alberio R, <i>et al.</i> , <i>Mammalian Oocyte Activation: Lessons from the Sperm and Implications for Nuclear Transfer</i> , INT J DEV BIOL 2001; 45: 797-809.	
		Baguisi A, <i>et al.</i> , <i>Production of Goats by Somatic Cell Nuclear Transfer</i> , NAT BIOTECH 1999; 17: 456-461.	
		Bondioli K, <i>et al.</i> , <i>Production of Identical Bovine Offspring by Nuclear Transfer</i> , THERIOGENOLOGY 1990; 33: 165-174.	
		Booth PJ, <i>et al.</i> , <i>Effect of Two Activation Treatments and Age of Blastomere Karyoplasts on In Vitro Development of Bovine Nuclear Transfer Embryos</i> , MOL REPROD DEV 2001; 60: 377-383.	
		Campbell, KHS, Mcwhire J, Ritchie WA And I. Wilmut. <i>Sheep Cloned by Nuclear Transfer From a Cultured Cell Line</i> , NATURE 1996; 380: 64-66.	
		Cibelli JB, <i>et al.</i> , <i>Cloned Transgenic Calves Produced From Nonquiescent Fetal Fibroblasts</i> . SCIENCE 1998; 280: 1256-1258.	
		Collas P, and Barnes FL., <i>Nuclear Transplantation by Microinjection of Inner Cell Mass and Granulosa Cell Nuclei</i> , MOL REPROD DEV. 1994 Jul;38(3):264-7.	
		Fissore A, <i>et al.</i> , <i>Inositol trisphosphate-induced calcium release in the generation of calcium oscillations in bovine eggs</i> , BIOL REPROD Oct. 1995; 53(4):766-774	
		Gavin, W.G., <i>Gene Transfer Into Goat Embryos</i> , TRANSGENIC ANIMALS – GENERATION AND USE, L. M. Houdebine ed., (Harwood Academic Publishers GmbH., 1996).	
Examiner Signature		Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.¹ Applicant's unique citation/designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901/04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

*Complete if Known***INFORMATION DISCLOSURE
STATEMENT BY APPLICANT***(use as many sheets as necessary)*

Sheet 3 of 4

Application Number 10/731,542

Filing Date December 3, 2003

First Named Inventor Esmail Behboodi

Art Unit 1632

Examiner Name

Attorney Docket Number GTC-60

		Kasinathan P, <i>et al.</i> , <i>Effect of Fibroblast Donor Cell Age and Cell Cycle on Development of Bovine Nuclear Transfer Embryos In Vitro</i> , BIOL REPROD. 2001; 64(5): 1487-1493.	
		Koo DB, <i>et al.</i> , <i>In Vitro Development Of Reconstructed Porcine Oocytes After Somatic Cell Nuclear Transfer</i> . BIOL REPROD 2000; 63: 986-992.	
		Lai, L, <i>et al.</i> , <i>Feasibility of Producing Porcine Nuclear Transfer Embryos by Using G2/M Stage Fetal Fibroblasts as Donors</i> , BIOL REPROD 2001; 65: 1558-1564.	
		Meng L, <i>et al.</i> , <i>Rhesus Monkeys Produced by Nuclear Transfer</i> , BIOL REPROD 1997; 57: 454-459.	
		Park KW, <i>et al.</i> , <i>Developmental Potential of Porcine Nuclear Transfer Embryos Derived from Transgenic Fibroblasts Infected with the Gene for the Green Fluorescent Protein: Comparison of Different Fusion/Activation Conditions</i> , BIOL REPROD 2001; 65: 1681-1685.	
		Ponimaskin E, <i>et al.</i> , <i>Sendai Virosomes Revisited: Reconstitution with Exogenous Lipids Leads to Potent Vehicles for Gene Transfer</i> , VIROLOGY, 2000 Apr 10;269(2):391-403.	
		Stice SL, <i>et al.</i> , <i>Pluripotent Bovine Embryonic Cell Lines Direct Embryonic Development Following Nuclear Transfer</i> , BIOL REPROD. 1996 Jan; 54(1):100-10.	
		Stice SL, and Keefer CL., <i>Multiple Generational Bovine Embryo Cloning</i> , BIOL REPROD 1993 Apr;48(4):715-9.	

Examiner
SignatureDate
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901/04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	4	of	4
-------	---	----	---

Application Number 10/731,542

Filing Date December 3, 2003

First Named Inventor Esmail Behboodi

Art Unit 1632

Examiner Name

Attorney Docket Number GTC-60

		Stice SL and JM Robl, <i>Nuclear Reprogramming in Nuclear Transplant Rabbit Embryo</i> , BIOL REPROD 1992; 47: 636-643	
		Wakayama T, et al., <i>Full Term Development of Mice from Enucleated Oocytes Injected with Cumulus Cell Nuclei</i> , NATURE 1998; 23: 369-374.	
		Wall RJ, et al., <i>Transgenic Dairy Cattle: Genetic Engineering on a Large Scale</i> , J DAIRY SCI. 1997; 80(9): 2213-24.	
		Wells DN, et al., <i>Production of Cloned Calves Following Nuclear Transfer with Cultured Adult Mural Granulosa Cells</i> , BIOL REPROD 1999; 60: 996-1005.	
		Westhusin ME, Pryor JH, and Bondioli KR., <i>Nuclear Transfer In The Bovine Embryo: A Comparison Of 5-Day, 6-Day, Frozen-Thawed, And Nuclear Transfer Donor Embryos</i> , Mol Reprod Dev. 1991 Feb;28(2):119-23.	
		Wilmot I, et al., <i>Viable Offspring Derived From Fetal and Adult Mammalian Cells</i> . NATURE 1997; 385: 810-813.	
		Yang X, S Jiang, A Kovacs and RH Foote, <i>Nuclear Totipotency of Cultured Rabbit Morulae to Support Full-Term Development Following Nuclear Transfer</i> , BIOL REPROD 1992; 47: 636-643.	
		Yong Z And L Yuqiang, <i>Nuclear-Cytoplasmic Interaction and Development of Goat Embryos Reconstructed by Nuclear Transplantation: Production of Goats by Serially Cloning Embryos</i> , BIOL REPROD 1998; 58: 266-269.	
		Zou X, et al., <i>Production of Cloned Goats from Enucleated Oocytes Injected with Cumulus Cell Nuclei or Fused with Cumulus Cells</i> , CLONING 2001; 3 (1): 31-37.	

Examiner Signature	Date Considered
-----------------------	--------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901/04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.